By now you’ve probably heard about the American Board of Psychiatry and Neurology’s (ABPN) new Maintenance of Certification (MOC) Program for psychiatrists. If you haven’t taken some action dictated by the new process, we have some bad news—you're probably already behind.
Read More
With new journals hatching frequently and a constant bombardment of information from multiple sources, it is getting more and more challenging to keep up to date.
Read More
Let me say from the outset that this program is still evolving, and what the final agreed upon requirements will look like continues to change, much to everyone’s frustration and to ABPN’s frustration as well.
Read More
As we reviewed in the July/August 2009 issue of TCPR (Vol 7, Issue 7), cardiac disease leads to major depression, and, conversely, depression is a risk factor for developing cardiac disease.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
KarXT (Cobenfy) is the first antipsychotic that doesn’t block dopamine. We trace the origins of this new drug to a South Asian herb used for over 5,000 years, up to the three...